A fixed-dose combination (FDC) medication used primarily for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that targets the polyol pathway, a key contributor to diabetic nerve damage. Pregabalin is a gabapentinoid that modulates calcium channels to provide neuropathic pain relief. This combination offers a dual-pathway approach: addressing the underlying metabolic pathology and providing symptomatic pain control.
Adult: One tablet of Epalrestat 150mg + Pregabalin 75mg twice daily (after morning and evening meals). May be initiated at a lower dose (e.g., once daily) in sensitive patients to improve tolerability.
Note: Administer orally with or immediately after meals to reduce potential gastrointestinal side effects and improve epalrestat tolerability. Tablet should be swallowed whole with a glass of water. Do not crush or chew.
The combination works via two distinct mechanisms. Epalrestat inhibits the enzyme aldose reductase, which converts glucose to sorbitol in the polyol pathway. In hyperglycemia, sorbitol accumulation leads to osmotic stress, oxidative damage, and impaired nerve conduction velocity. By inhibiting this pathway, Epalrestat aims to slow the progression of diabetic neuropathy. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (e.g., glutamate, substance P). This results in analgesic, anxiolytic, and anticonvulsant effects, providing symptomatic relief from neuropathic pain.
Pregnancy: Pregabalin: Category C (US FDA). Animal studies showed teratogenicity. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Epalrestat: Data insufficient. This combination should be avoided in pregnancy unless absolutely necessary. Counsel women of childbearing potential.
Driving: PATIENTS MUST BE WARNED. This drug may cause dizziness, somnolence, blurred vision, and reduced concentration. Patients should not drive, operate complex machinery, or engage in hazardous activities until they know how the medication affects them, especially during dose initiation and titration.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Potentiated sedation, dizziness, respiratory depression, and increased risk of accidents. | Major |
| Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Enalapril) | Increased risk and severity of peripheral edema and angioedema. | Major |
| Thiazolidinediones (Pioglitazone, Rosiglitazone) | Additive risk of fluid retention, edema, and weight gain. | Moderate |
| Other Antidiabetic Agents (Insulin, Sulfonylureas) | Pregabalin may cause weight gain, potentially affecting glycemic control. No direct pharmacokinetic interaction. | Moderate |
| Loop Diuretics (Furosemide) | May reduce the efficacy of furosemide. Monitor for edema. | Moderate |
Same composition (Epalrestat (150mg) + Pregabalin (75mg)), different brands: